ReviewLung cancer in never smokers – A review
Introduction
Tobacco use is the oldest1 and most well-established2 risk factor for lung cancer. However, this malignancy occurs in a very small number of patients who have no history of smoking. Lung cancer in never smokers (LCINS) has only been described in detail in the past 5 years3, 4, 5 and its frequency is increasing according to some authors. LCINS has been found to be accessible via targeted treatments, and thus has become the subject of major research.6, 7 The present article focused on providing an in-depth literature review of LCINS.
A ‘never smoker’ is commonly defined as an individual who has smoked less than 100 cigarettes over his or her lifetime. Never smokers are thus differentiated from ‘ever smokers’ (more than 100 cigarettes over their lifetime), who are normally sub-categorised as either ‘ex-smokers’, i.e. those who have currently and completely stopped smoking for more than 1 year, and ‘current smokers’, i.e. those who currently smoke or have quit for less than 1 year.3, 8 The concept of ‘light smoker’ lacks clarity and is debatable, as there is no tobacco threshold effect for the risk of lung cancer. In IPASS study, authors have defined light smokers as people who have smoked less than 10PY in their lifetime and quit smoking since at least 15 years.9 This cut-off value seems henceforth too high. Although no official definition has been established, a history of less than 5 pack-years is now commonly thought of as light smoking. Debate continues on where the reported incidence of LCINS in recent years represents a true increase. In 2001, Bofetta et al. observed a significant increase in the incidence of LCINS in a Swedish cohort: from 1.5/100 000 in 1976–1980 to as much as 5.4/100,000 in 1991–1995.10 Their results seemed to confirm earlier observations suggesting a progressive increase in LCINS since the 1930s11, 12 and the emergence of non-tobacco related lung cancer risks. However, in a large analysis of cohorts and registries, Thun et al. observes no significant temporal trend in LCINS incidence and mortality among United States of America (US) never smokers from 1959 to 2004.13, 14 The authors of a recent work found a decrease incidence in men but increase in women when compared to the preceding generation.15 Leaving methodology debates aside, an increase in LCINS incidence could be real, or the result of the decrease in the proportion of ever smokers in some strata of the general population, and/or ageing within these categories.16
The World Health Organisation estimates that 25% of lung cancer worldwide occurs in never smokers.17 This percentage is probably closer to 10–15% in Western countries. However, LCINS proportions vary widely, from more than 50% in women in Southeast Asia, to approximately 2–6% in men in Western series.3, 8, 18 If considered as an independent entity, LCINS is the 7th largest cause of cancer-related mortality in the world19 and a top-ten cause of death in the United States.14, 20 In France a study of the Bas Rhin registry found LCINS proportions of 1.4% and 28.9% respectively in men and women21; within the KBP-2000 study, these proportions were 2.5% and 32.3%.22 Comparing these results to cancer mortality estimations for France in 2011,23 LCINS represents the 3rd-leading cause of death by cancer in women. At the European level, data from the European Cancer Observatory24 show that LCINS is the 17th cause of cancer mortality (9th for women, see Supplementary Fig.1). There is thus a considerable geographical effect, particularly in women, for LCINS. Indeed, the malignancy is more frequently diagnosed in Asia than it is in the United States, and more frequently in the United States than in Europe. However its ethnic/genetic attributes and/or environmental factures remain unknown.3
Section snippets
Clinical and pathological presentation
In all LCINS series, women are systematically over-represented.3, 5, 6, 8, 25 Mortality rates in female patients are of the same as for male patients.14
Contradictory data exist concerning age and diagnoses of LCINS, with some authors reporting the cancer’s penchant for older patients, while others find it in significantly younger patients. The data from several French studies tend to illustrate a predominance of LCINS in advanced-age patients. In the KBP-2000 study, the proportion of never
Lung cancer risk factors other than smoking (Table 1)
Lung cancer in individuals who do not smoke obviously suggests the existence of risk factors other than tobacco (Table 1).3, 8, 18, 29 These other risk factors are in no way found exclusively in never smokers; indeed, different risk factors, related or not to smoking, are frequently associated and sometimes cumulative or synergic. Several epidemiological studies have identified several factors associated with risk of lung cancer. From those, most are linked to pollution: occupational,
Genomic polymorphisms(Table 2)
Polymorphisms of genes involved in carcinogen metabolism are very relevant and productive for smokers with lung cancer.
Two polymorphisms in exon 7 of CYP1A1, the substitutions T3801C (MspI) and A2455G (Ile462Val), are linked to an increased risk of lung cancer.94 Specifically in Caucasian never smokers (in data pooled from 14 studies) there was a significant effect for the Ile462Val mutation (OR = 2.21 [95% CI = 1.12–4.37]) but a non-significant effect for the MspI mutation. 95 The Leu432Val
P53 mutations
There is a linear relation between p53 mutation risk and tobacco consumption123; mutations are thus rarer in never smokers (10–47%) than in ever smokers (26–71%).124 Additionally, the spectrum and type of mutation differ according to smoking status: G to T transversions are more frequently found in ever smokers, whereas G to A transitions and G to C transversions are more common in never smokers.123, 124 Finally, it is interesting to note that p53 mutations are more frequent in never-smoker
Conclusion
Lung cancer in never smokers is a distinct medical entity that is more frequent in women than in men and in certain geographical regions than in others (Asia > North America > Europe). Pollution (including environmental tobacco smoke and occupational exposure) is an important factor in this population. Close to 50% of never-smoker patients present molecular mutations that may be treatable currently or in the near future via targeted therapies compared to potentially 10% of ever smokers.
The genomic
Conflict of interest statement
SC declares having received grants, paid to his institution from: Roche SA France, Pfizer, Boeringher Ingelheim, Pierre Fabre, Astra Zeneca and Lilly. GZ declares having received grants, paid to his institution from Lilly and supports for travel to meeting from Lilly. FM: None declared. BM: None declared. PJS: None declared.
References (150)
Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis
Lung Cancer
(2001 Mar)Lung cancer in never smokers: a new hot area of research
Lancet Oncol
(2010)- et al.
Specific features of non-small cell lung cancer in women: a retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997
J Thorac Oncol
(2007) - et al.
Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20,561 cases
Ann Oncol
(2002) - et al.
Management and outcome of French elderly patients with lung cancer: an IFCT survey
Rev Mal Respir
(2010) - et al.
Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan
J Thorac Oncol
(2010) - et al.
Small cell lung cancer in never smokers: report of two cases
J Thorac Oncol
(2010) - et al.
Characteristics of never smoker lung cancer including environmental and occupational risk factors
Lung Cancer
(2010) - et al.
Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries
Lancet
(2011) - et al.
Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers
Biochem Biophys Res Commun
(2001)
The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers
J Thorac Cardiovasc Surg
Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma
Hum Pathol
Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung
Lung Cancer
Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women
Lung Cancer
Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial
Lancet
Menopausal hormone therapy and risk of lung cancer-Systematic review and meta-analysis
Maturitas
Atmospheric air pollution and lung cancer: epidemiologic data
Rev Mal Respir
Air pollution and lung cancer risks in China – a meta-analysis
Sci Total Environ
Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study
J Thorac Oncol
Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs
J Thorac Oncol
Characteristics of thoracic malignancies that occur after solid-organ transplantation
J Thorac Oncol
Alcohol consumption and lung cancer risk in never smokers: a meta-analysis
Ann Oncol
The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients
Metab Clin Exp
Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer
Lung Cancer
Prolonged survival in patients with lung cancer with diabetes mellitus
J Thorac Oncol
The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects
Lung Cancer
Smoking and carcinoma of the lung; preliminary report
Br Med J
Lung cancer in never smokers – a different disease
Nat Rev Cancer
Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity
J Clin Oncol
Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival
Cancer
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases
J Clin Oncol
Nonsmall cell lung cancer in never smokers
Curr Opin Oncol
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
N Engl J Med
Incidence of lung cancer in a large cohort of non-smoking men from Sweden
Int J Cancer
Indirect estimates of lung cancer death rates in Italy not attributable to active smoking
Epidemiology
Rising lung cancer mortality among nonsmokers
J Natl Cancer Inst
Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies
PLoS Med
Lung cancer death rates in lifelong nonsmokers
J Natl Cancer Inst
Novel epidemiology in lung cancer - non-smokers, women and cannabis
Rev Mal Respir
Generational risks for cancers not related to tobacco, screening, or treatment in the United States
Cancer
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Int J Cancer
Lung cancer in never smokers: a review
J Clin Oncol
Global cancer statistics, 2002
CA Cancer J Clin
Lung cancer among nonsmokers
Epidemiology
Epidemiologic of primary bronchial carcinoma management in the general French hospital centers
Rev Mal Respir
Lung cancer in never smokers: clinical epidemiology and environmental risk factors
Clin Cancer Res
Exposure to environmental tobacco smoke and risk of lung cancer: the epidemiological evidence
Eur Respir J
The accumulated evidence on lung cancer and environmental tobacco smoke
BMJ
Cited by (376)
Bidirectional Association Between Cardiovascular Disease and Lung Cancer in a Prospective Cohort Study
2024, Journal of Thoracic OncologyEligibility to lung cancer screening among staffs of a university hospital: A large cross-sectional survey
2023, Respiratory Medicine and ResearchEvaluating county-level lung cancer incidence from environmental radiation exposure, PM<inf>2.5</inf>, and other exposures with regression and machine learning models
2024, Environmental Geochemistry and Health